Latest news with #DexCom
Irish Independent
3 days ago
- Health
- Irish Independent
‘It's peace of mind when your blood sugar levels are consistent' – Liam Nolan aims to join fellow diabetes sufferer JJ Spaun at The Open
The Galway golfer (25) lies ninth in the race for 20 DP World Tour cards after racking up three top-four finishes in his first ten starts on the second-tier HotelPlanner Tour. There's a long way to go before the Barna, Co Galway native can dream of teeing it up on the main tour next year, but he resumes work in France next week with a spring in his step and some big goals. Not only has he signed a new sponsorship deal with DexCom, a global leader in real-time continuous glucose monitoring for people with diabetes, but he's also excited about building on a great start to the season and trying to qualify for The Open for the second year running. 'I'm delighted,' said Nolan, who watched with interest as fellow Type 1 diabetes suffering Spaun upstaged the stars to win the US Open at Oakmont on Sunday. 'Dexcom make those continuous glucose monitors, and they've just opened up their main manufacturing site for Europe in Galway, which will provide 1,000 jobs. 'So I was very excited when that happened and then they got the naming rights for Connacht's rugby stadium, which is the Dexcom stadium now. 'It just seemed like a perfect fit, me being from Galway, being a type one diabetic, and having a degree in Biomedical Engineering, it just made good sense. And they saw it the same way. So we were able to do a deal. Which is amazing.' Nolan was diagnosed as Type 1 diabetic when he was 14, but while Spaun was misdiagnosed initially as Type 2 in 2018, he got the correct diagnosis in 2021 and hasn't looked back. 'He started playing really well when he got the right treatment and it was great to see him win,' Nolan said. 'He definitely played the best.' Nolan was never misdiagnosed, but he has been playing brilliantly since turning professional and knows that close control of his condition is key. ADVERTISEMENT Learn more 'I have probably the best control over my blood sugar levels that I've ever had,' said Nolan, who, like Spaun, wears a blood sugar monitor on the course. 'And that frees you up to go and perform in every tournament. 'It's like a peace of mind thing when your blood sugar levels are consistent and within the right kind of parameters.' Nolan has not been quite as consistent on the course but while he has missed six cuts, most were by small margins and he's looking to build on his start to the season over the summer months. 'It's hard to know how your first year as a pro is going to go like you,' said the former Walker Cup player, who takes as much confidence from grinding to make the cut as he does from contending. 'You want to be confident in your own ability, but there's a bit of uncertainty there, so it's nice to know that my game kind of stacks up well to the pro life.' His next run of tournaments features the Irish Challenge at Killeen Castle in August, but he's also looking forward to competing in Final Qualifying for The Open at Dundonald Links on July 1. 'I qualified for The Open at Dundonald Links last year, so hopefully that'll conjure up some good memories,' Nolan said. 'It's just a really good test of ball striking and you're pretty much guaranteed the most wind and adverse conditions of any of the qualifying spots, which is why I went there last year. So I'm delighted to be going back there.' Nolan missed the cut at Royal Troon and admitted he was on cloud nine all week. But he plans to treat it like any other event if he qualifies this time around. 'I learned so much last year and prepared not how I would prepare for any other tournament, just because of how excited I was to be there,' he said. 'I was a bit giddier than I usually would be at a golf tournament. So, hopefully, all is going well this year; I want to go back to The Open but prepare how I would prepare for any other tournament. 'It was good to play my first major as an amateur, and make your mistakes then and learn from them. But I also wouldn't change how I prepared last time because it was a dream come true.' As for securing his DP World Tour card via the HotelPlanner Tour rankings, he admits he's not a fan of looking at where he stands in the Road to Mallorca list. 'I just try and go and play and try and win,' he explained. 'I don't think it benefits me knowing where I am.' As one of the more health-conscious players on tour, he won't be playing non-stop but choosing his schedule carefully before re-assessing things before the last few crucial events when the cards are on the line. 'I'll keep my head down until after the Dutch Challenge,' he said. 'When I'm at a tournament, I like to be fully rested and ready to go. I have a great team around me and great support, and DexCom is a great addition.'
Business Wire
10-06-2025
- Business
- Business Wire
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and purported market share. However, beginning on April 25, 2024, DexCom made its first in a series of public corrective disclosures announcing that the company's growth and business prospects were far lower than it had previously claimed. By the time the company made its final corrective disclosure on July 25, 2024, the price of DexCom's shares had plummeted by over 40.6%. Current stockholders who held their DexCom stock before April 28, 2023, are encouraged to contact Johnson Fistel to discuss their legal rights in this matter. You can click or copy and paste the following link to join this investigation: About Johnson Fistel, PLLP: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Business Insider
30-05-2025
- Business
- Business Insider
DexCom initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of DexCom (DXCM) with a Buy rating and $104 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and DexCom offers potential upside from consumer-related adoption and strong profitability leverage that should evidence through the balance of 2025, the analyst tells investors in a research note. The market also underappreciates the degree of P&L upside in DexCom model as gross margins scale, Goldman Sachs added. Confident Investing Starts Here:
Yahoo
28-05-2025
- Business
- Yahoo
Prediction: These 2 Stocks Will Beat the Market in the Next Decade
Eli Lilly and DexCom have been market-beaters over the past decade. Eli Lilly could ride the wave of a strong lineup and deep pipeline, especially in weight management. DexCom's devices are valuable to diabetes patients, but there's still a significant untapped opportunity. 10 stocks we like better than Eli Lilly › Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies. Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and DexCom (NASDAQ: DXCM). Eli Lilly has been one of the best-performing pharmaceutical giants in the past 10 years. Though that doesn't guarantee future success, it's worth highlighting what has led to the company's strong showing. Lilly has made significant clinical breakthroughs in recent years, none more important than tirzepatide, a medicine sold as Mounjaro in treating diabetes, and Zepbound in managing weight. It was the first dual GLP-1/GIP agonist approved by the U.S. Food and Drug Administration. Here are two ways in which that's relevant to the company's future performance. First, tirzepatide hasn't been on the market that long, having earned approval about three years ago. It will continue delivering excellent top-line growth. Second, even more clinical successes like tirzepatide could help the stock perform well. Eli Lilly recently released positive data from a phase 3 clinical trial for orforglipron, an oral GLP-1 medicine; the strong results sent the stock price soaring. The drugmaker is also working on retatrutide, which mimics the action of not just two gut hormones (as tirzepatide does), but three. Lilly dubbed it "triple G." Retatrutide could be yet another breakthrough. In total, the company has 11 weight loss candidates in the pipeline. Even with mounting competition in this field, Eli Lilly looks like a runaway leader compared to any company not named Novo Nordisk. And that's before we mention the rest of the pipeline. Last year, Lilly earned approval for Kisunla in treating Alzheimer's disease, another significant win considering that very few medicines have gotten the green light from regulators in this area in the past 20 years. Lilly has not performed well in 2025 due to tariff-induced volatility, and disappointing bottom-line guidance for the full year. However, the company is pivoting its manufacturing back into the U.S., something it has been doing for years -- so even if President Donald Trump's trade agenda survives his administration, the drugmaker should be fine. And while the stock's forward price-to-earnings ratio of around 33 is around twice the average of 16 for the healthcare industry, the company's better-than-average results and excellent prospects justify its valuation. Eli Lilly is a terrific dividend stock. The company has increased its payouts by 200% over the past 10 years. And the stock should deliver superior returns through 2035, especially for shareholders who opt to reinvest the dividend. DexCom specializes in developing and marketing continuous glucose monitoring (CGM) systems that help diabetes patients keep track of their blood sugar levels. The company's appeal is the superiority of its devices compared to the alternatives. With blood glucose meters, patients use a painful finger prick (or something similar) to collect a small blood sample to know their measurement at that specific point in time. In contrast, once installed, CGMs constantly monitor their status, day and night, with measurements made up to every five minutes. That's 12 per hour and 288 per day -- no manual meter can match that. Strong adoption of the technology has been a massive tailwind for DexCom. Patients are switching to CGM, and third-party payers are increasingly reimbursing for it. This has resulted in growing revenue and earnings over the past decade, and a strong, if somewhat volatile, stock-market performance. Here's more good news: DexCom has consistently pointed out that the CGM market remains underpenetrated. In the U.S., the number of diabetes patients who use CGM is much lower than the number whose use would be covered by insurance. Furthermore, the company has routinely entered new markets to expand its addressable population. DexCom does have to deal with stiff competition from Abbott Laboratories, but has remained successful nonetheless. Abbott pointed out about 18 months ago that just 1% of diabetic adults worldwide had access to CGM. So there's space for multiple winners over the long run. And while tariffs could be a threat, DexCom does significant manufacturing for U.S. consumers domestically. Management expects minimal impact from tariffs. Lastly, though DexCom's recent forward P/E of around 42 looks high, it's not far from the lowest point it has seen in years: A high-growth stock, DexCom has generally traded at high premiums and has still performed better than the broader market. Its valuation won't kill momentum in the next decade. And in the meantime, the stock should once again deliver outsize returns as DexCom makes headway into the massive CGM market. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Novo Nordisk and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. Prediction: These 2 Stocks Will Beat the Market in the Next Decade was originally published by The Motley Fool Sign in to access your portfolio
Globe and Mail
27-05-2025
- Business
- Globe and Mail
Prediction: These 2 Stocks Will Beat the Market in the Next Decade
Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies. Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and DexCom (NASDAQ: DXCM). 1. Eli Lilly Eli Lilly has been one of the best-performing pharmaceutical giants in the past 10 years. Though that doesn't guarantee future success, it's worth highlighting what has led to the company's strong showing. Lilly has made significant clinical breakthroughs in recent years, none more important than tirzepatide, a medicine sold as Mounjaro in treating diabetes, and Zepbound in managing weight. It was the first dual GLP-1/GIP agonist approved by the U.S. Food and Drug Administration. Here are two ways in which that's relevant to the company's future performance. First, tirzepatide hasn't been on the market that long, having earned approval about three years ago. It will continue delivering excellent top-line growth. Second, even more clinical successes like tirzepatide could help the stock perform well. Eli Lilly recently released positive data from a phase 3 clinical trial for orforglipron, an oral GLP-1 medicine; the strong results sent the stock price soaring. The drugmaker is also working on retatrutide, which mimics the action of not just two gut hormones (as tirzepatide does), but three. Lilly dubbed it "triple G." Retatrutide could be yet another breakthrough. In total, the company has 11 weight loss candidates in the pipeline. Even with mounting competition in this field, Eli Lilly looks like a runaway leader compared to any company not named Novo Nordisk. And that's before we mention the rest of the pipeline. Last year, Lilly earned approval for Kisunla in treating Alzheimer's disease, another significant win considering that very few medicines have gotten the green light from regulators in this area in the past 20 years. Lilly has not performed well in 2025 due to tariff-induced volatility, and disappointing bottom-line guidance for the full year. However, the company is pivoting its manufacturing back into the U.S., something it has been doing for years -- so even if President Donald Trump's trade agenda survives his administration, the drugmaker should be fine. And while the stock's forward price-to-earnings ratio of around 33 is around twice the average of 16 for the healthcare industry, the company's better-than-average results and excellent prospects justify its valuation. Eli Lilly is a terrific dividend stock. The company has increased its payouts by 200% over the past 10 years. And the stock should deliver superior returns through 2035, especially for shareholders who opt to reinvest the dividend. 2. DexCom DexCom specializes in developing and marketing continuous glucose monitoring (CGM) systems that help diabetes patients keep track of their blood sugar levels. The company's appeal is the superiority of its devices compared to the alternatives. With blood glucose meters, patients use a painful finger prick (or something similar) to collect a small blood sample to know their measurement at that specific point in time. In contrast, once installed, CGMs constantly monitor their status, day and night, with measurements made up to every five minutes. That's 12 per hour and 288 per day -- no manual meter can match that. Strong adoption of the technology has been a massive tailwind for DexCom. Patients are switching to CGM, and third-party payers are increasingly reimbursing for it. This has resulted in growing revenue and earnings over the past decade, and a strong, if somewhat volatile, stock-market performance. DXCM Revenue (Annual) data by YCharts. Here's more good news: DexCom has consistently pointed out that the CGM market remains underpenetrated. In the U.S., the number of diabetes patients who use CGM is much lower than the number whose use would be covered by insurance. Furthermore, the company has routinely entered new markets to expand its addressable population. DexCom does have to deal with stiff competition from Abbott Laboratories, but has remained successful nonetheless. Abbott pointed out about 18 months ago that just 1% of diabetic adults worldwide had access to CGM. So there's space for multiple winners over the long run. And while tariffs could be a threat, DexCom does significant manufacturing for U.S. consumers domestically. Management expects minimal impact from tariffs. Lastly, though DexCom's recent forward P/E of around 42 looks high, it's not far from the lowest point it has seen in years: DXCM PE Ratio (Forward) data by YCharts. A high-growth stock, DexCom has generally traded at high premiums and has still performed better than the broader market. Its valuation won't kill momentum in the next decade. And in the meantime, the stock should once again deliver outsize returns as DexCom makes headway into the massive CGM market. Should you invest $1,000 in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor 's total average return is957% — a market-crushing outperformance compared to167%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends DexCom and Novo Nordisk and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy.
